Repurposing drugs for the management of COVID-19
Jacopo Cusinato, Ylenia Cau, Anna Maria Calvani, Mattia Mori
Abstract
: Drug repurposing proved highly successful in response to the current pandemic, with remdesivir becoming the first specific antiviral drug approved for the treatment of COVID-19. In parallel, a number of drugs such as corticosteroids and low molecular weight heparin (LMWH) are used to treat hospitalized COVID-19 patients, while clinical testing of additional therapeutic options is ongoing. It is reasonably expected that these research efforts will deliver optimized and specific therapeutic tools that will increase the preparedness of health systems to possible future epidemics.
Topics & Concepts
RepurposingCoronavirus disease 2019 (COVID-19)Drug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus2019-20 coronavirus outbreakMedicineIntensive care medicineDrug developmentDrugDiseasePharmacologyInfectious disease (medical specialty)VirologyBiologyOutbreakEcologyPathologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing